[HTML][HTML] Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review

JP Sequeira, S Salta, R Freitas, R López-López… - Cancers, 2024 - mdpi.com
Simple Summary PCa remains a leading health concern worldwide. Serum PSA-based PCa
screening led to a well-documented decreased mortality but at the cost of the increased …

Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review

JP Sequeira, S Salta, R Freitas, R López-López… - …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Prostate cancer (PCa) is one of the most frequently occurring malignancies.
Although most cases are not life-threatening, approximately 20% endure an unfavorable …

[HTML][HTML] Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review

JP Sequeira, S Salta, R Freitas, R López-López… - Cancers, 2024 - ncbi.nlm.nih.gov
Background: Prostate cancer (PCa) is one of the most frequently occurring malignancies.
Although most cases are not life-threatening, approximately 20% endure an unfavorable …

Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review.

JP Sequeira, S Salta, R Freitas, R López-López… - Cancers, 2024 - europepmc.org
Background Prostate cancer (PCa) is one of the most frequently occurring malignancies.
Although most cases are not life-threatening, approximately 20% endure an unfavorable …

Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review.

JP Sequeira, S Salta, R Freitas, R López-López… - …, 2024 - search.ebscohost.com
Abstract Simple Summary: PCa remains a leading health concern worldwide. Serum PSA-
based PCa screening led to a well-documented decreased mortality but at the cost of the …

Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review.

JP Sequeira, S Salta, R Freitas, R López-López… - Cancers, 2024 - europepmc.org
Background Prostate cancer (PCa) is one of the most frequently occurring malignancies.
Although most cases are not life-threatening, approximately 20% endure an unfavorable …